1μg (R: reducing condition, N: non-reducing condition).
Product Details
Product Details
Product Specification
Species | Human |
Synonyms | C-X-C motif chemokine 9; MIG; CXCL9; CMK; SCYB9 |
Accession | Q07325 |
Amino Acid Sequence | Thr23-Thr125 |
Expression System | E.coli |
Molecular Weight | 15kDa (Reducing) |
Purity | >95% by SDS-PAGE |
Endotoxin | <0.1EU/μg |
Conjugation | Unconjugated |
Tag | No Tag |
Physical Appearance | Lyophilized Powder |
Storage Buffer | PBS, pH7.4 |
Reconstitution | Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation. |
Stability & Storage | · 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles. |
Reference | J Immunol. 2004 Jun 15;172(12):7417-24. Exp Cell Res. 2021 Oct 15;407(2):112801. Epub 2021 Aug 27. |
Background
Monokine induced by IFN-gamma (MIG; CXC chemokine ligand (CXCL)9) is important in T lymphocyte recruitment in organ transplantation. MIG/CXCL9 stimulate CD4 lymphocyte proliferation in a MHC class II-mismatched MLR and also increased the number of IFN-gamma-producing CD4 lymphocytes in ELISPOT. Neutralization of MIG/CXCL9 in MLR reduced T lymphocyte proliferation, IFN-gamma-inducible protein 10/CXCL10 and IFN-inducible T cell alpha chemoattractant/CXCL11 had similar effects on T lymphocyte proliferation. MIG/CXCL9 stimulated T lymphocyte proliferation in MHC class I-and total MHC-mismatched MLRs. Neutralization of CXCR3 reduced MIG/CXCL9-induced T lymphocyte proliferation and the number of IFN-gamma-positive spots on ELISPOT.The proliferative effects of MIG/CXCL9 were mediated via an IL-2-independent pathway and were controlled by IFN-gamma.
Picture
Picture
SDS-PAGE
